Elysium Health has announced a study into the effects of NAD+ supplementation in menopausal women has found that its flagship NAD+ product, Basis, can improve disruptive menopausal symptoms
The open-label pilot study included 40 healthy women aged 35 and above, 32 of whom self-reported symptoms associated with the menopausal transition and eight of whom were not experiencing any (or minimal) symptoms associated with menopause
After seven days of Basis supplementation, participants reported any changes in the frequency and severity of several of the most disruptive menopause symptoms, including hot flashes, bloating and poor sleep
Key findings
The study, published inFrontiers in Aging, demonstrated that women taking Basis had significantimprovements in disruptive menopausal symptoms.
The research also found a significant increase in the ratio of estradiol (E2) to estrone (E1), two key forms of estrogen, restoring it to a more favourable balance
Estradiol (E2) and estrone (E1) are the main forms of estrogen in women and their balance shifts during menopause. The study’s results therefore suggest a link between NAD+ metabolism and estrogen balance
The authors also noted the characterisation of a previously unreported NAD+ metabolite, which could provide new insights into NAD+ metabolism and utilisation
“This study stemmed from my own experience with Basis helping with menopausal symptoms,” said Dr MarieMigaud, study co-author, Elysium Health research collaborator and Brian Metcalf Chair in Chemical Biology at The University of Western Australia
“From that experience, we hypothesised that supporting NAD+ metabolism could help promote a healthier balance between estradiol and estrone during menopause.”
We were encouraged to see improvements in estradiol-to-estrone ratios alongside meaningful reductions in the frequency and severity of menopausal symptoms reported by participants
Dr Migaud added that the unexpected discovery of the new NAD+ metabolite highlighted how much remains to be learned about NAD+ biology
“The identification of a previously unreported NAD+ metabolite in this study broadens our understanding of how NAD+ precursors are processed and utilised in humans,” said Dr Ryan Dellinger, study co-author and VP of Scientific Affairs at Elysium
As the field moves beyond simply measuring NAD+ levels, a more complete understanding of NAD+ metabolism will yield more insights into healthy ageing.
The authors said the study’s results were promising, suggesting a potential link among NAD+ metabolism, estrogen balance and menopausal symptoms
Although additional research will be necessary, the findings lay the groundwork for larger, more rigorous studies to explore the role of NAD+ support in women’s health
Elysium said it intends to conduct further clinical research into the topic, including a larger randomised, placebo-controlled trial
